Why to watch out Spain

The Spanish biotech sector is growing. This attracts more and more international investors. End of September ASEBIO organised the first edition of an Investor Day. 
Read more

Evotec acquires stake in Exscientia

German CRO Evotec AG announced an €15m investment in British Exscienta Ltd. to push artificial intelligence (AI)-driven drug discovery.

Read more

Genmab bags €25m milestone upon market approval of daratumumab

Danish Genmab A/S has received market approval in Japan for its anti-CD38 antibody daratumumab (DARZALEX®) as therapy for relapsed or refractory Multiple Myeloma.

Read more

Newron raises CHF27m

Neurology specialist Newron Pharmaceuticals S.p.A. (Milan) has raised gross proceeds of CHF 27m through a private placement of new shares via an accelerated book-building process.

Read more

EU approves Roche’s atezolizumab for bladder cancer

Though not reaching the overall surival endpoint in Phase III, the European Commission has granted label extension for Roche’s checkpoint blocker Tecentriq in two types of metastatic bladder cancer.

Read more

Da Volterra bags €20m EIB investment

French microbiota specialist Da Volterra has received an EIB loan to speed up development of treatments that prevent antibiotic resistance and hospital acquired infections.

Read more

microRNA blocks life-threatening ARDS

A team of US and German researchers has found that neutrophils secrete a regulatory RNA  into lung tissue that protects against harmful inflammations. 

Read more

Vesalius Biocapital and IFD launch life sciences fund

Healthcare investor Vesalius Biocapital has created a new investment vehicle in collaboration with the Portuguese National Promotional bank (IFD) aimed at investing in Portuguese life science companies.

Read more

Immunocore nabs US$40m from Gates Foundation

British T cell receptor specialist Immunocore Ltd will receive a US$40m investment from the the Bill & Melinda Gates Foundation  to develop immunotherapies that fight tuberculosis and HIV.

.

Read more

Polpharma: Making biologics economic

After having set up a R&D hub for the biomanufacturing of clinical trial supplies in Gdansk, Polpharma is expanding its European footprint with a €100m investment in Warsaw. Several take-overs previously made the company a one-stop shop for biomanufacturing. European Biotechnology spoke with Federico Pollano, Director Contract Manufacturing and Business Development at the CDMO and bio­similars maker, about Polpharma’s strategy and expansion of biologics production. 
Read more